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Edited by Bernd HelmsAbstract The key mechanism in prion disease is the conversion
of cellular prion protein into an altered, pathogenic conforma-
tion, in which cellular mechanisms play a poorly understood role.
Both forms of prion protein are lipid-anchored and reside in rafts
that appear to protect the native conformation against conver-
sion. Neurons rapidly traﬃc their cellular prion protein out of
its lipid rafts to be endocytosed via coated pits before recycling
back to the cell surface. It is argued in this review that under-
standing the mechanism of this traﬃcking holds the key to
understanding the cellular role in the conformational conversion
of prion protein.
 2006 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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The prion diseases1 are caused by a normal cell surface pro-
tein, prion protein (PrPC; superscript C denotes the normal cel-
lular form) adopting an alternative conformation with
markedly increased b-pleated sheet content that aggregates
to form amyloid ﬁbrils and plaques within the brain, with
accompanying fatal neurodegeneration [1].
This conversion occurs spontaneously at an extremely low
rate. In man, spontaneous CJD kills people at a frequency of
1 in a million of the population, and then only in old age.
The low spontaneous frequency can be greatly increased by
mutations within PrP, with some invariably causing fatal dis-
ease in homozygotic carriers [1]. Some of these disease-causing
mutations have been shown to destabilize the normal confor-
mation of PrPC, but others, particularly in the unstructured
N-terminal domain, do not discernibly aﬀect PrPC itself and*Corresponding author. Fax: +44 20 7848 6816.
E-mail address: roger.morris@kcl.ac.uk (R.J. Morris).
1 The prion diseases, classed overall as transmissible spongiform
encephalopathies (TSE), are grouped in man as Creutzfeldt–Jacob
Disease (CJD), Gerstmann–Straussler–Scheinker disease (GSS), fatal
familial insomnia (FFI) and kuru; in cattle and mink, bovine/mink
spongiform encephalopathy; in North American deer as chronic
wasting disease; and in sheep and goats, or in TSE from another
species transferred to mice, as scrapie.
0014-5793/$32.00  2006 Federation of European Biochemical Societies. Pu
doi:10.1016/j.febslet.2006.07.053so probably inﬂuence the protein’s interaction with other pro-
teins, either with infectious PrPRes or with normal cellular pro-
teins such as those involved in its traﬃcking [2].
Conversion can also be triggered, very eﬃciently, by the
introduction of even minute quantities of infectious PrPRes
via food, wounds, grafting or contamination on surgical
instruments.2 The bovine spongiform encephalopathy epi-
demic (BSE, or mad cow disease) in the UK dramatically dem-
onstrated the high eﬃciency of infection within a single species,
and its capacity to cross species to infect man, albeit at low
incidence.
This combination of aetiology by spontaneous, inherited
and infectious routes is unique for a disease dependent upon
the product of a single gene, and gives the prion diseases a spe-
cial place in investigating the role of protein misfolding in neu-
rodegeneration. Unlike, for instance, Alzheimer’s disease, for
which the cumulative eﬀect of triple gene knockouts is required
to produce a reasonable experimental model, genetically nor-
mal mice can be infected with mouse adapted scrapie. It is
not a model system, it is the disease. Questions such as whether
neurodegeneration begins by damage to pre-synaptic axon ter-
minals (a candidate cause of neurodegeneration in a range of
misfolding diseases) can be examined with precision in scra-
pie-infected mice [3].2. Prion protein misfolding and amyloid formation
Since the key interaction in prion disease is between the cel-
lular and pathogenic conformations of a single protein, the
simplest mechanism is to posit a direct interaction between
PrPC and the infectious PrPRes form. This ‘protein chemistry
only’ view can be represented by schemes such as that shown
in Fig. 1.
Studies of prion infectivity show that monomers and small
oligomers of PrPRes are not infectious, it is mid-sized oligomers2 The altered, infectious conformation of PrP is relatively resistant to
proteolysis, a property often used to identify this form which is
designated PrPRes. Where the infectious form is identiﬁed by infectious
titre, it is usually designated PrPSc for the Scrapie form. PrPRes is a
subset of, but not identical to, PrPSc, probably because a single
standard set of conditions are used to deﬁne protease resistance, but
diﬀerent strains of prion disease show diﬀerent degrees of resistance.
Infectious PrPSc of some prion strains can be destroyed by the
stringent proteolysis that detects most of the PrPSc as PrPRes in other
strains. Here we use PrPRes to denote protease-resistant infectious
prions.
blished by Elsevier B.V. All rights reserved.
Fig. 1. Scheme of prion amyloid formation, emphasizing that until
stable mid-sized oligomers of PrPRes (represented as squares) are
formed, equilibria (or kinetic barriers) favour the normal conforma-
tion of monomer PrPC (represented as spheres), with small oligomers
(<hexomer; rectangles) being metastable or otherwise less eﬀective in
seeding further conversion of PrPC. The initial step in spontaneous and
familial disease is the conversion of PrPC to the metastable monomer,
which with repeated cycles builds up and converts to the seeding
oligomer. Infectious disease short-cuts this process by introducing
seeding oligomer.
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that it is an oligomer, not the monomer, that seeds amyloid
formation simpliﬁes a long-standing problem in prion re-
search: how to explain the existence of many diﬀerent ‘strains’
of prion disease. ‘Strain’ (used here in analogy to viral strains)
refers to the fact that diﬀerent types of prion disease can vary
so markedly in the type of pathology (±plaques, ±spongiform
degeneration), the areas of the brain attacked, the major cells
aﬀected (neurons vs astrocytes or even vascular endothelia)
and the timing of disease progression (from months to many
years), that they can appear to be entirely diﬀerent diseases.
It is clear, from relative protease sensitivity and exposure of
epitopes to antibodies, that PrPRes also diﬀers molecularly in
diﬀerent prion strains [5]. But how could a single protein en-
code this range of multiple disease types as diﬀerent conforma-
tions? The problem becomes much more understandable if the
information is encoded, not in the conformation of a mono-
mer, but in that of oligomers which could be assembled in mul-
tiple ways.3. Conversion of PrPC is chaperoned by cells
Prion disease cannot be analysed purely as a problem of pro-
tein chemistry. As with other protein folding diseases, how the
target protein PrPC is folded, traﬃcked and degraded within
the cell plays a central role in the disease. Evidence for this
ranges from the diﬃculty of producing infectious amyloid that
mimics in vivo disease in cell-free conditions [6] to studies of the
eﬀect of mutations that control PrPC traﬃcking or membrane
anchorage upon prion infection [7,8]. And since PrPC and
PrPRes are tethered to the surface membrane by glycosylphos-
phatidylinositol (GPI) anchors, their partitioning into lipid
rafts is a key component.
The inﬂuence of membrane rafts upon PrPC traﬃcking and
its conversion to PrPRes, and wider issues of PrPC function and
dysfunction in disease, are the subject of some excellent recent
reviews [9–12] that tackle a formidable and often conﬂicting
array of data. Major problems (not restricted to PrP) that im-
pede decisive experimentation include the lack of speciﬁc
means to alter rafts within cells; doubt concerning the use of
detergent resistant membranes (DRMs) as isolates of rafts;
and the diﬃculty of visualizing compartmentalization of raft
proteins on living cells.
Here, we focus upon a single question – how does the traf-
ﬁcking of PrPC on neurons aﬀect its interaction with PrPRes?
From this vantage point, we will also comment upon some
wider methodological problems.4. Endocytic traﬃcking of a GPI-anchored protein
Endocytic traﬃcking is not an autonomous property of a
protein, but rather requires it to interact with other molecules
in its environment. The textbook example is endocytosis via
coated pits, for which endocytic adaptor proteins (e.g. AP2,
b-arrestin) bind to traﬃcking motifs present on the cytoplas-
mic domain of transmembrane proteins. GPI-anchored pro-
teins, lacking any cytoplasmic domain, can be endocytosed
through coated pits by binding extracellularly to a transmem-
brane receptor that has the requisite endocytic motifs on its
cytoplasmic domain. The prototypical example is the uPA
receptor-PA1 inhibitor complex that binds extracellularly to
the LDL receptor-related protein 1 (LRP1), which has the req-
uisite cytoplasmic traﬃcking motifs and is rapidly endocytosed
via coated pits [13]. Aggregate properties of rafts are suggested
to also drive alternative, non-coated pit endocytosis, by mech-
anisms that remain to be clariﬁed.
Since clathrin and its adaptors are ubiquitously and very
highly expressed, the endocytosis of a transmembrane protein
can be studied by transfecting it into any convenient cell. How-
ever, for a GPI-anchored protein such as PrPC, there can be no
guarantee that its transfection into a non-expressing cell, or
even into a native expressing cell at excess levels, will result
in its interaction with the full range of molecules that normally
internalize the protein. If the native mechanism is not avail-
able, other mechanisms will take over, the default being bulk
ﬂow into endocytic organelles resulting in the 16-18h internal-
ization times reported for PrPC in a number of studies (see re-
views [11,12]).
Caveolae are irrelevant to prion traﬃcking on neurons as
cavealae do not occur on adult mammalian neurons. No mem-
brane in biology has been examined ultrastructurally as min-
utely and repeatedly as the neuronal surface for the past 50
years, without to our knowledge caveolae ever being reported
on adult mammalian neurons. Caveolae are seen on accessory
and glial cells (in some cases, in abundance, such as on peri-
neurial cells and Schwann cell myelin in peripheral nerve),
which explains the presence of caveolin proteins in neural
homogenates.5. PrPC traﬃcking on the neuronal surface
We have studied the endocytic traﬃcking of endogenously
expressed PrPC on primary cultured adult sensory neurons,
by labelling the protein with ﬂuorochrome- or gold-coupled
Fab antibody fragment (i.e. a monovalent ligand) at a sub-
endocytic temperature (10–15 C), and then raising the temper-
ature to 37 C to allow endocytosis (Figs. 2A, B and 3). We
found that PrPC leaves its rafts to recycle every few minutes
via clathrin coated pits between the cell surface and recycling
endosomes [14]. PrPC on the neural cell line N2a traﬃcs simi-
larly [14,15], although with ten times slower kinetics [14] as
does transfected PrPC on SH-SY5Y neural cells (although here
the process of leaving rafts requires the presence of Cu2+ [16]
which is not the case with sensory neurons).
The distinctive feature of this traﬃcking is that, while still on
the cell surface, PrPC leaves its raft environment to cross non-
raft membrane and then enter coated pits, where (still not in
rafts) it is endocytosed and returned to the surface (Fig. 2).
Fig. 2. Fluorescent views of PrPC seen in optical sections through
sensory neurons. (A, B) Living neurons were pulse labelled at 10 C
with Alexa 488-Fab to PrPC (green) and Alexa 594-transferrin (red),
taken to 37 C and ﬁxed and examined after 0 min (A) or 2 min
(B). Arrows point to neuronal surface; most transferrin and PrPC
label is in sorting endosomes by 2 min. (C,D) Compares labelling for
cell surface (green) and internal (red) protein, for PrPC (C) and Thy-1
(D); chromatin is labelled blue with DAPI. Living neurons were
labelled at 10 C with Alexa 488-conjugated Fab, the cells washed,
ﬁxed and permeabilized, then labelled with Alexa 594 (red) Fab
to disclose internal antigen. See [14] for details. Scale bars are
10 lm.
Fig. 3. Electron micrograph views of PrPC (labelled with the smaller
5 nm gold-Fab particles throughout) during endocytosis. (A) A living
neuron, labelled with 5 nm gold-Fab to PrPC, was incubated at 37 C
for 2 min, the surface membrane torn oﬀ by adhesion to a laminin-
coated EM grid which was immediately ﬁxed, and the cytoplasmic face
of the membrane then labelled with 10 nm gold-IgG to the endocytic
adaptor AP2. The membrane is being viewed from the cytoplasmic
side, the forming coated pits appear as small ‘hills’ that contain almost
all the AP2 label, and most of the PrPC label at this stage. (B,C)
Examples of PrPC immunolabelling at 0 min incubation at 37 C, when
most PrPC immunolabel is found on the ‘plains’ and not near coated
pits (arrows point to the nearest AP2 label in the vicinity). At this
stage, >80% of PrPC labelled is in Brij 96-resistant membrane, so we
believe these clusters of PrPC are in rafts. (D)–(G) Conventional
transmission electron micrograph sections, showing clusters of PrP
with transferrin (10 nm label). In D, a single transferrin label occurs in
the midst of the central cluster of PrPC; further examples are shown in
E and F. G shows PrPC and transferrin entering a coated pit together.
Scale bars are 50 nm, see [14] for more detail.
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and returned to the cell surface within 6 min [14]. The speed
of this traﬃcking is best grasped by ﬁlm – see supplementary
Film. The relatively short life of PrPC on the cell surface,
compared to its transit of endocytic recycling compartments,
means that the pool of internalized PrPC should be a
major component in neurons. This can readily be seen by com-
paring internal with surface labelling for PrPC and Thy-1, a
control (non-endocytosed) neuronal GPI-anchored protein
(Fig. 2C and D) [14]. Immunohistochemistry for PrPC in
mouse brain showed a substantial pool of intracellular, vesi-
cle-bound protein in neurons, reﬂecting this endocytic traﬃck-
ing [17].
The GPI anchor is the prototypical raft-localization signal;
its substitution on PrPC by a transmembrane polypeptide
changes the membrane environment of the protein so that it
is no longer insoluble in cold non-ionic detergent, and so argu-
ably no longer a raft protein [8]. By the same criterion, there is
a second raft-localization domain within the ﬁrst 28 amino
acids of the N-terminal domain of PrPC that can bind soluble
(GPI-less) PrPC to rafts, and relocate chimeric transmembrane
proteins into rafts [18,19]. Finally, the disulﬁde loop in the C-
terminal domain of PrPC (between 179Cys and 214Cys) has the
structure and binding properties of a sphingolipid-binding
domain [20] that would also direct PrPC to sphingolipid-rich
rafts.
With three raft-localization signals, how is it that PrPC
spends so much of its time (Fig. 4) recycling outside rafts?6. Evidence that PrPC leaves its rafts for endocytosis
The observation that ﬁrst suggested that PrPC left its raft
environment for endocytosis came from EM immunogold
labelling of cells at diﬀerent times during endocytosis. As endo-
cytosis progressed, PrPC moved progressively closer and then
into coated pits, often in close association with the prototypi-
cal ‘non-raft’ transmembrane protein, the transferrin receptor
(Fig. 3 and [14]). This suggested that, just before its endocyto-
sis, PrPC was in normal ‘non-raft’ membrane. To test this,
we used surface biotinylation with a reduction-cleavable
Fig. 4. Scheme of PrPC recycling at the cell surface of neurons, with
the approximate half-life of PrPC in the diﬀerent compartments shown.
PrPC rafts are represented by darker surface membrane; EnR
represents the transmembrane endocytic partner of PrPC.
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PrPC, and PrPC that had been endocytosed since labelling.
The cells were then solubilized in non-ionic detergents and
ﬂoated on density gradients to separate the low density deter-
gent-resistant membrane (DRM) fraction, often equated with
the raft fraction, from the fully solubilized ‘non-raft’ proteins
[14]. By this criterion, 15% of the surface PrPC was initially
in fully solubilized (non-raft) membrane at 0 s, as was all endo-
cytosed PrPC at later time points. A similar approach was used
to demonstrate that Cu2+ draws PrPC out of rafts prior to its
endocytosis on SH-SY5Y cells [16].
These two observations unpin our contention that PrPC
leaves its rafts to be endocytosed. But does the changing solu-
bility of a protein in cold non-ionic detergents during endocy-
tosis demonstrate a changing membrane environment of these
proteins, in or out of rafts on the cell surface at 37 C? The rea-
sons for considering DRMs to be artefacts of solubilization are
well rehearsed (e.g. [21,22]) and in one respect we agree with
this case. The ‘gold standard’ detergent used to isolate DRMs,
Triton X-100, causes mixing of fragments from totally diﬀerent
membranes into single DRM vesicles [23]. Triton X-100 also
scrambles inner with outer leaﬂet components in DRM vesicles
[24]. Both properties are probably a consequence of Triton X-
100’s ability to selectively remove phospholipids of the inner
leaﬂet membrane (phosphatidyl-ethanolamine, -inositol and
-serine) [25,26] which would leave the single outer leaﬂet highly
unstable in an aqueous environment, unless it merged with
others. Triton X-100 therefore gives at best a mixture, primar-
ily of the outer leaﬂets of rafts, a property that prevents any
comparison with the nano-scale mosaicism of membrane lipids
and proteins in living cells.
However, other non-ionic detergents such as Brij 96 leave
approximately equimolar amounts of inner and outer leaﬂet
lipids in their DRMs [26] do not mix DRMs from entirely dif-
ferent membranes [23] and retain the outer/inner leaﬂet asym-
metry of the cellular membrane [24]. Is it then possible to
isolate discrete fragments of insoluble plasma membrane using
Brij 96 that accurately represent the surface membrane sur-
rounding PrPC at 37 C? We set a very simple criterion: PrPC
is present on the neuronal surface along with Thy-1. As judged
by monovalent EM immunolabelling of the cell surface
(whether at 10 C or 37 C, or on glutaraldehyde-ﬁxed or liv-
ing cells) these two GPI-proteins are clustered into adjacent,but mostly non-overlapping, domains on the neuronal surface,
presumably reﬂecting their very diﬀerent traﬃcking
[14,17,23,28]. Could they be separately immunoisolated using
Brij 96?
Both proteins are expressed by all major neurons and not by
glia in healthy adult brain [17,27] so that brain membranes
provide a simple in vivo source in which both proteins are only
on neuronal membrane. Brij 96 DRMs were prepared from
brain membranes and separate Thy-1 and PrPC fractions ob-
tained by immunoprecipitation. These diﬀered, highly repro-
ducibly and signiﬁcantly, in their content of individual lipids,
with the PrPC DRMs being 10% less saturated, but with a
higher cholesterol content, than the Thy-1 DRMs [28]. The
biological implications of these diﬀerences is lipid are intrigu-
ing [28], but for the current discussion two points are impor-
tant.
The ﬁrst is that Brij 96 reproducibly yielded, as separate
DRMs, two GPI-anchored proteins that occupy diﬀerent
microdomains on the neuronal surface. Without claiming that
Brij 96 DRMs are complete raft membranes, the detergent has
reproducibly dissected out the nm-scale domain structure of
Thy-1 and PrPC. And since PrPC (but not Thy-1) always has
a fully solubilized (non-raft) component in neuronal mem-
branes [23] we suggest we are justiﬁed in concluding that PrPC
transits from a detergent-resistant (raft) environment into a
detergent-soluble (non-raft) environment for coated pit endo-
cytosis.
Second, endocytosed PrPC has a distinctive lipid environ-
ment that would be expected to restrict access to PrPC of a dis-
tinct class of transmembrane protein, e.g. as an endocytic
partner.7. Transmembrane endocytic partner(s) of PrPC
The N-terminal domain of PrPC is both necessary and suﬃ-
cient for coated pit endocytosis [12,14,29], for which the imme-
diate N-terminal basic residues (NH2KKRPKP-) or PrPC are
essential [14].
This motif has been identiﬁed as a major heparan sulfate/
glycosoaminoglycan binding site of PrPC [30,31]. We found
that enzymatic removal of sulfates from the neuronal surface
slowed the rate of PrPC endocytosis by 20% (Deng J. et al.,
unpublished, quoted in [14]), suggesting that heparan sulfates
may be part of the endocytic complex of PrPC.
Basic residues are, however, well established binding motifs
for extracellular cargo (including the uPA-PA1 inhibitor com-
plex referred to above [13]) binding to the constitutively endo-
cytosed LDL receptor-related protein (LRP1), for which
heparan sulfate/glycosoaminoglycans act as co-receptors (e.g.
[32]). Current work in our laboratory (in progress) ﬁnds, by
a combination of inhibition by competitive ligand antagonism,
siRNA knockdown, and chemical cross-linking with immuno-
precipitation, that member(s) of the LDL-receptor related pro-
tein (LRPs) control the traﬃcking of endogenously expressed
PrPC on neurons.
A very diﬀerent LRP is also reported to bind to recombinant
PrP (i.e. soluble PrP without glycan chains or membrane an-
chor). The non-integrin 37 kDa laminin receptor precursor
(LRP) and its mature 67 kDa laminin receptor (LR) were
found, initially in a yeast dihybrid screen [33] then conﬁrmed
by expression on mammalian cells [33–35] to bind recombinant
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ribosomes/nucleus [36] and on the cell surface [34]. They bind
recombinant PrP primarily at residues 144–179 in the C-termi-
nal domain [35] and internalize it over 18 h [34]. Little within
this work suggests this protein might interact on the neuronal
surface with endogenously expressed PrPC. However, knock-
down of this protein by antisense or siRNA completely and
stably removed PrP GPI anchor from scrapie-infected cell cul-
tures [37]. Given the range of side eﬀects that are becoming
apparent with this technology, the negative controls used
should perhaps be revisited, but this work does argue for a crit-
ical role of the LRP/LR receptors in prion infection.
Another cytoplasmic protein that also occurs on the cell sur-
face and can there bind recombinant PrP is stress-inducible
protein 1 [38]; again, there is little to suggest this is the interac-
tive partner for PrPC endocytosis on neurons.8. Rafts and the production of PrPRes
A variety of evidence indicates that rafts protect against con-
version of PrPC to PrPRes. Thus, in their cell free conversion
system, Caughey and colleagues ﬁnd that GPI-anchored PrPC
present in detergent-insoluble membranes3 is resistant to con-
version by PrPRes, unless its GPI anchor is cleaved by phosp-
halipase C to release soluble PrPC from the DRMs, or the
normal and infected membranes are fused by high levels of
polyethylene glycol (which would disrupt raft structure) [39].
This result could be reproduced using PrPC attached to raft-
mimicking liposomes of cholesterol-sphingolipids provided it
was GPI-anchored. GPI-anchorless PrP, attached to the
microsomes only by the alternative N-terminal domain bind-
ing site, was readily converted [18]. This suggests that the
GPI anchor stabilizes the conformation of PrPC within rafts
to resist conversion, a conclusion supported by recent studies
of the eﬀect of membrane upon the conformation of recombi-
nant PrP. When anchored to a bilayer by a GPI anchor or mi-
metic, PrP adopts its native conformation [40,41] in contrast to
the membrane perturbation of the conformation of non-GPI
anchored recombinant PrP shown in earlier studies.
Studies of prion infection within cells further argues for a
protective role of rafts. Raft depletion by inhibition of sphin-
gomyelin production increased scrapie infection in cultured
cells [42]; and cholesterol depletion increased the proportion
of misfolded PrPC in the endoplasmic reticulum [43,44]. Rafts
may provide a very simple mechanism to protect against the
conversion process. Two diﬀerent studies of DRMs, isolated
from cells and infected brain using Triton X-100, found that
PrPRes ﬂoated at slightly higher density than PrPC [45,46] sug-
gesting that the two forms of PrP may be sequestered on the
cell surface in diﬀerent compartments, preventing their interac-
tion.
Against such evidence must be weighed experiments showing
that substitution of a transmembrane polypeptide for PrP’s
GPI anchor directs the protein into normal, rather than deter-
gent-insoluble, membrane and prevents scrapie infection in
cultured cells [8,47]. The unique lipid composition of PrPC
rafts [28] presumably directs access of a speciﬁc subset of trans-3 These authors call cellular PrP, PrPsen, to denote sensitivity to
conversion in their assay.membrane proteins, adapted to this environment, to PrPC. The
requirement of PrPC to have a raft-localizing GPI anchor may
be to ensure eﬃcient interaction with its transmembrane part-
ner, which in turn may be the critical step for eﬀective interac-
tion with PrPRes.9. Role of traﬃcking in the pathogenic conversion of PrPC to
PrPRes
Disease associated mutant forms of PrPC are misfolded and
retained by chaperones in the ER for abnormal periods [43,48]
suggesting that in familial CJD conversion towards the patho-
genic form may occur from the earliest biosynthetic stages.
Scrapie infection in a transgenic mouse in which PrP was
tagged with GFP showed accumulation of aggregated GFP-
PrP in the Golgi from mid-stage disease [49]. However, exten-
sive ultrastructural immunohistochemical studies of various
mouse and sheep scrapies have found PrPResdeposits at the cell
surface/intercellular space, and in lysosomes, but not signiﬁ-
cantly in Golgi [50]. GFP-PrP may indicate the accumulation
of a disease-related form of PrP that is not robust enough to
be seen by EM immunolabelling (possibly the metastable inter-
mediate of Fig. 1); or perhaps be another example of diﬀerent
pathology associated with diﬀerent scrapie strains.
In tissue culture, one scrapie infected cell line (SMB cells) re-
quired direct surface contact of apposing cells to transfer infec-
tion; glutaraldehyde ﬁxation of the infectious source reduced,
but did not prevent, infection, suggesting that contact, but
not exchange of infectious agent, between the cells is necessary
for infection [51]. The same conclusion is suggested by studies
of infection delivered by adherence to stainless steel wire: a sin-
gle infected sample of wire can be used to infect multiple brains
or cells, without any apparent diminution in titre [52] suggest-
ing that infection does not depend on removing PrPRes from
the wire, but in having cells contact it there. Furthermore,
the infected wire need only be inserted in recipient brain for
30 min to induce infection. Insertion causes local damage,
and the contact time of the infected wire with healthy cells
must be limited, implying that in vivo infection is initiated with-
in minutes, not the hours to days taken for amyloid formation
by isolated proteins.
However, in other systems infected cell supernatant is highly
infectious, due possibly to exosomes secreted by the cells. Pas-
sage of endocytosed material to lysosomes can be via multive-
sicular bodies, where in some (but probably not all) cells,
vesicles bud to form exosomes in which GPI-anchored proteins
are selectively enriched [53]. These exosomes are released from
the cell and can travel considerable distances before binding to
and fusing with target cells [53]; those released by some scrapie
infected cells carry infection [54]. Thus endocytosis can initiate
a mechanism that spreads infection eﬃciently around a tissue
or body.
If the meeting of PrPC and PrPRes occurs at the cell surface,
but not within rafts, it is the brief period between PrPC leaving
rafts, and PrPC and PrPRes going in diﬀerent directions after
endocytosis, the former into recycling endosomes, the latter
into lysosomes, that is available for their critical interaction
to trigger the conformational conversion of PrPC. It would
seem there has to be some powerful mechanism to bring the
two forms of prion protein together at this stage to allow the
pathogenic interaction to occur.
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the endocytic receptors for both PrPC and PrPRes. The latter
is not PrPC itself, but is an independent receptor [55], possibly
the non-integrin laminin receptor precursor [37] or heparan
sulfate [56]. However, the N-terminal domain of PrP, so vital
in the interaction of the cellular protein with its transmem-
brane endocytic partner, is not altered by the conformational
conversion to PrPRes (which involves residues 90–231) [1]
and so presumably can bind the endocytic partner of PrPC.
The same receptor could well endocytose both PrPC and
PrPRes.10. Questions in place of a summary
The problem of how cells chaperone the conversion of PrPC
to PrPRes is complex. This area is poised to develop rapidly, so
in place of a summary, we close with some questions.
1. Do PrPC and PrPRes occupy the same, or separate, rafts on
infected neurons?
2. What is the receptor(s) that internalizes both PrPC, and
PrPRes?
3. Is this endocytic partner polyvalent – can it simultaneously
bind both PrPC and PrPRes? If so, do they have access to
each other? (Could the receptor act as an infectious scaﬀold,
bringing together substrate PrPC and template PrPRes?)
4. Should this receptor(s) bring together PrPC and PrPRes on
the cell surface, does the eﬃciency of interaction in this
scaﬀold depend upon the size of PrPRes oligomers? Could
pentomers and smaller not be large enough to contact eﬃ-
ciently PrPC bound at another site on the receptor; and very
large oligomers (ﬁbrils) immobilize the receptor and
monopolize its binding sites, preventing access of PrPC?
Which would leave medium-size oligomers as the infectious
entity, without any need to posit the metastable intermedi-
ate of Fig. 1.Appendix A. Supplementary data
Supplementary data associated with this article can be
found, in the online version, at doi:10.1016/j.febslet.2006.07.
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